- Home
- NCMI vs NGNE Comparison
NCMI vs NGNE Comparison
Compare NCMI & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCMI
- NGNE
- Stock Information
- Founded
- NCMI 2005
- NGNE 2003
- Country
- NCMI United States
- NGNE United States
- Employees
- NCMI N/A
- NGNE N/A
- Industry
- NCMI Advertising
- NGNE Biotechnology: Pharmaceutical Preparations
- Sector
- NCMI Consumer Discretionary
- NGNE Health Care
- Exchange
- NCMI Nasdaq
- NGNE Nasdaq
- Market Cap
- NCMI 414.7M
- NGNE 426.6M
- IPO Year
- NCMI 2007
- NGNE N/A
- Fundamental
- Price
- NCMI $3.94
- NGNE $26.66
- Analyst Decision
- NCMI Strong Buy
- NGNE Strong Buy
- Analyst Count
- NCMI 4
- NGNE 8
- Target Price
- NCMI $6.88
- NGNE $44.75
- AVG Volume (30 Days)
- NCMI 523.5K
- NGNE 244.5K
- Earning Date
- NCMI 10-30-2025
- NGNE 11-18-2025
- Dividend Yield
- NCMI 3.06%
- NGNE N/A
- EPS Growth
- NCMI N/A
- NGNE N/A
- EPS
- NCMI N/A
- NGNE N/A
- Revenue
- NCMI $236,300,000.00
- NGNE N/A
- Revenue This Year
- NCMI $3.33
- NGNE N/A
- Revenue Next Year
- NCMI $13.09
- NGNE N/A
- P/E Ratio
- NCMI N/A
- NGNE N/A
- Revenue Growth
- NCMI N/A
- NGNE N/A
- 52 Week Low
- NCMI $3.91
- NGNE $6.88
- 52 Week High
- NCMI $7.60
- NGNE $74.49
- Technical
- Relative Strength Index (RSI)
- NCMI 37.45
- NGNE 44.34
- Support Level
- NCMI $4.04
- NGNE $27.28
- Resistance Level
- NCMI $4.56
- NGNE $32.99
- Average True Range (ATR)
- NCMI 0.19
- NGNE 3.06
- MACD
- NCMI -0.01
- NGNE -1.06
- Stochastic Oscillator
- NCMI 0.81
- NGNE 20.28
About NCMI National CineMedia Inc.
National CineMedia Inc is a cinema advertising platform in the U.S. It derives revenue from the sale of advertising to national, regional and local businesses through The Noovie Show, the cinema advertising and entertainment show seen on movie screens across the U.S., on LEN, a series of strategically-placed screens located in movie theater lobbies, as well as other forms of advertising and promotions in theater lobbies.
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.